Skip to main content
. 2015 Sep 22;142(18):3077–3084. doi: 10.1242/dev.126482

Fig. 1.

Fig. 1.

hPSC-derived cell therapeutics advancing to clinical testing. hPSC-derived cell therapeutics advancing to clinical testing include retinal pigment epithelium (RPE) for retinal degenerative diseases, dopaminergic neurons (Neurons) for Parkinson's disease, cardiomyocytes for heart disease, oligodendrocyte progenitor cells (OPCs) for spinal cord injury and β-islet cells (β cells) for diabetes.